Drug
Persantin New Formulation
Persantin New Formulation: highest development phase Phase 1, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Persantin® new formulation NCT02259998 | Phase 1 | Healthy |
Latest
No recent events.
Follow Persantin New Formulation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.